Malloy J, et al. - Researchers examined the safety and tolerability, pharmacokinetics and preliminary efficacy of a novel methionine aminopeptidase 2 (MetAP2) inhibitor, ZGN-1061 with regard to glucose control. This trial consisted of a single ascending dose (SAD) phase in healthy subjects (BMI, 23 to <30 kg/m²) and a multiple ascending dose (MAD) phase in otherwise healthy subjects (BMI, 27 to 40 kg/m²). No severe or serious adverse events were reported. It was determined that all doses of ZGN-1061 were rapidly absorbed and cleared, leading to a short duration of exposure that was anticipated to minimize potential off-drug target risks. Yielded results demonstrated ZGN-1061 was well tolerated with no safety signals in all doses tested.